118 related articles for article (PubMed ID: 14712519)
1. [Detection and clinical significance of plasma urokinase-type plasminogen activator and its soluble receptor in patients with multiple myeloma].
Luo LH; Xu GB; Lu XG
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Dec; 32(6):529-32. PubMed ID: 14712519
[TBL] [Abstract][Full Text] [Related]
2. Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
Jensen MK; Riisbro R; de Nully Brown P; Brünner N; Hasselbalch HC
Eur J Haematol; 2002 Jul; 69(1):43-9. PubMed ID: 12270061
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
[TBL] [Abstract][Full Text] [Related]
4. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
[TBL] [Abstract][Full Text] [Related]
6. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
7. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients.
Rigolin GM; Tieghi A; Ciccone M; Bragotti LZ; Cavazzini F; Della Porta M; Castagnari B; Carroccia R; Guerra G; Cuneo A; Castoldi G
Br J Haematol; 2003 Mar; 120(6):953-9. PubMed ID: 12648064
[TBL] [Abstract][Full Text] [Related]
10. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of urokinase-type plasminogen activator (uPA) and its soluble receptor (suPAR) in patients with atopic eczema/dermatitis syndrome.
Kasperska-Zajac A; Rogala B
Inflammation; 2005 Apr; 29(2-3):90-3. PubMed ID: 16858643
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase-type plasminogen activator levels are related to plasma cytokine levels but have low predictive value for mortality in trauma patients.
Timmermans K; Vaneker M; Scheffer GJ; Maassen P; Janssen S; Kox M; Pickkers P
J Crit Care; 2015 Jun; 30(3):476-80. PubMed ID: 25721031
[TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
14. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
15. [Urokinase plasminogen activator (u-PA) and urokinase type plasminogen activator receptor (u-PAR) in children with ulcerative colitis].
Grabarczyk E; Szaflarska-Popławska A; Góralczyk K; Adamska I; Rość D
Med Wieku Rozwoj; 2007; 11(1):41-4. PubMed ID: 17965463
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.
Lawn SD; Myer L; Bangani N; Vogt M; Wood R
BMC Infect Dis; 2007 May; 7():41. PubMed ID: 17509133
[TBL] [Abstract][Full Text] [Related]
17. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
[TBL] [Abstract][Full Text] [Related]
18. Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.
Abdellatif HAA; Sultan BO; Nassar HM; Gomaa MEE; Sakr MG; Riad E; Al-Harbi AI; Abdulhakim JA; Fawzy MS; Abd El-Fadeal NM
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108340
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
20. [Plasma suPAR level in patients with multiple myeloma].
Wang W; Wang HY; Cui ZG; Wang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):197-9. PubMed ID: 18315930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
